These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242 [TBL] [Abstract][Full Text] [Related]
3. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956 [TBL] [Abstract][Full Text] [Related]
4. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184 [TBL] [Abstract][Full Text] [Related]
5. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380 [TBL] [Abstract][Full Text] [Related]
6. Ticagrelor: a novel reversible oral antiplatelet agent. Nawarskas JJ; Clark SM Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E; Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826 [TBL] [Abstract][Full Text] [Related]
8. The PLATO trial: do you believe in magic? Serebruany VL; Atar D Eur Heart J; 2010 Apr; 31(7):764-7. PubMed ID: 20007979 [TBL] [Abstract][Full Text] [Related]
9. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. James S; Budaj A; Aylward P; Buck KK; Cannon CP; Cornel JH; Harrington RA; Horrow J; Katus H; Keltai M; Lewis BS; Parikh K; Storey RF; Szummer K; Wojdyla D; Wallentin L Circulation; 2010 Sep; 122(11):1056-67. PubMed ID: 20805430 [TBL] [Abstract][Full Text] [Related]
10. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM; Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Mariani M; Mariani G; De Servi S Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763 [TBL] [Abstract][Full Text] [Related]
12. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome. Packard KA; Campbell JA; Knezevich JT; Davis EM Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457 [TBL] [Abstract][Full Text] [Related]
14. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Toth PP Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814 [TBL] [Abstract][Full Text] [Related]
15. Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. De Servi S; Navarese EP; D'Urbano M; Savonitto S Curr Med Res Opin; 2011 Nov; 27(11):2117-22. PubMed ID: 21919581 [TBL] [Abstract][Full Text] [Related]
16. Ticagrelor (Brilinta)--better than clopidogrel (Plavix)? Med Lett Drugs Ther; 2011 Sep; 53(1372):69-70. PubMed ID: 21897348 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. Anderson SD; Shah NK; Yim J; Epstein BJ Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464 [TBL] [Abstract][Full Text] [Related]
18. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology. Clemmensen P; Dridi NP; Holmvang L Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983 [TBL] [Abstract][Full Text] [Related]